Cargando…
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients(1), yet harbours mutation-derived T cell neoantigens that are suitable for vaccines (2,3). Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, w...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171177/ https://www.ncbi.nlm.nih.gov/pubmed/37165196 http://dx.doi.org/10.1038/s41586-023-06063-y |